So, you want to get better at Java coding? That’s awesome. The thing is, just watching videos or reading books only gets you so far. You really need to get your hands dirty and write some code.

So, you want to get better at Java coding, huh? It’s a pretty popular language, and honestly, getting some hands-on practice is the best way to really learn it. Luckily, there are a bunch of places ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence. December 8, 2025 Recursion Pharma's ...

Community driven content discussing all aspects of software development from DevOps to design patterns. To do that, you need practice, and that’s what this collection of GH-300 GitHub Copilot practice ...

Stay up to speed on the latest INDYCAR news, behind-the-scenes driver content, exclusive offers and more — delivered straight to your inbox! By subscribing you ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...